<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24926349</article-id><article-id pub-id-type="pmc">4043570</article-id><article-id pub-id-type="doi">10.3892/etm.2014.1642</article-id><article-id pub-id-type="publisher-id">etm-07-06-1591</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Effects of differenta mitomycin C concentrations on laser-assisted subepithelial keratectomy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>SHI</surname><given-names>JIANJIANG</given-names></name><xref ref-type="corresp" rid="c1-etm-07-06-1591"/></contrib><contrib contrib-type="author"><name><surname>YUAN</surname><given-names>YAOXIN</given-names></name></contrib><contrib contrib-type="author"><name><surname>ZHAO</surname><given-names>SUXIA</given-names></name></contrib><contrib contrib-type="author"><name><surname>XU</surname><given-names>JIANLONG</given-names></name></contrib><contrib contrib-type="author"><name><surname>GUO</surname><given-names>MENG</given-names></name></contrib><aff id="af1-etm-07-06-1591">Department of Ophthalmology, Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei 054000, P.R. China</aff></contrib-group><author-notes><corresp id="c1-etm-07-06-1591">Correspondence to: Dr Jianjiang Shi, Department of Ophthalmology, Second Affiliated Hospital of Xingtai Medical College, No. 1628 Quanbei West Street, Xingtai, Hebei 054000, P.R. China, E-mail: <email>jianjiangshicn@126.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>28</day><month>3</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>3</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>7</volume><issue>6</issue><fpage>1591</fpage><lpage>1594</lpage><history><date date-type="received"><day>20</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014, Spandidos Publications</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions><abstract><p>The aim of the present study was to determine the effect of different concentrations of mitomycin C (MMC) administered intraoperatively during laser-assisted subepithelial keratectomy (LASEK) surgery. A total of 261 patients (496 eyes) were randomly divided into two groups: 0.04% MMC treatment group consisting of 133 patients (245 eyes) and the 0.02% MMC treatment group consisting of 128 patients (251 eyes). The MMC solutions were dropped intraoperatively onto the ablation region and the duration was dependent on the preoperative refractive power of the patient&#x02019;s cornea: &#x02264;&#x02212;3.00 diopters (D), 30 sec; between &#x02212;3.25 D and &#x02212;6.00 D, 60 sec; between &#x02212;6.25 D and &#x02212;9.00 D, 90 sec and &#x02265;&#x02212;9.25 D, 110 sec. Postoperative observations included haze formation, visual acuity, changes in refractive power, corneal endothelial cell density and incidence of complications. The one year postoperative incidence of haze differed significantly between the groups (P&#x0003c;0.05). The one week and one year comparisons of postoperative visual acuity also differed significantly between the groups (P&#x0003c;0.05). Postoperative changes in corneal refractive power at one, six and 12 months following surgery significantly differed between the groups (P&#x0003c;0.05). No statistically significant difference was identified between the density of corneal endothelial cells prior to surgery and the density at one, six and 12 months following surgery (P&#x0003e;0.05). Thus, the intraoperative application of 0.04% MMC solution effectively inhibited haze formation and markedly improved the efficacy of LASEK surgery, when compared with that of 0.02% MMC.</p></abstract><kwd-group><kwd>laser-assisted subepithelial keratectomy</kwd><kwd>mytomycin C</kwd><kwd>haze</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Laser-assisted subepithelial keratectomy (LASEK) surgery was introduced in 1999 to eliminate the flap-related complications of laser-assisted <italic>in situ</italic> keratomileusis (LASIK) surgery. The LASEK surgical procedure reduces significant postoperative pain, corneal haze and prevents the flap and interface-related problems associated with LASIK surgery (<xref rid="b1-etm-07-06-1591" ref-type="bibr">1</xref>). Furthermore, LASEK surgery increases visual acuity and decreases aberrations and other defects (<xref rid="b2-etm-07-06-1591" ref-type="bibr">2</xref>). Patients undergoing LASEK surgery reportedly have reduced risks of postoperative ectasia, indicating that this surface treatment may be safer, particularly when the patients are highly myopic or have thin corneas. However, other complications remain, including haze and regression, which limit the development of LASEK surgery. The present study investigated the postoperative effects of administering different concentrations of mitomycin C (MMC) during LASEK surgery.</p></sec><sec sec-type="methods"><title>Patients and methods</title><sec><title>Patients</title><p>A total of 261 patients were enrolled in the present study. The subjects were aged &#x02264;18 years and were scheduled to undergo LASEK surgery between June 2007 and June 2008. This study was a prospective, randomized, single-center study and all surgical procedures were performed by one surgeon. The 0.04% MMC group comprised 133 patients (245 eyes), including 58 males (112 eyes) and 75 females (113 eyes), aged between 18 and 46 years (mean age, 23.7 years). A total of 28 patients (51 eyes) exhibited low myopia [&#x02264;&#x02212;3.00 diopters (D)], 39 patients (71 eyes) exhibited medium myopia (between 3.25 D and &#x02212;6.00 D), 31 patients (55 eyes) exhibited high myopia (between 6.25 D and 9.00 D) and 35 patients (68 eyes) exhibited extremely high myopia (&#x02265;&#x02212;9.25 D). The 0.02% MMC group comprised 128 patients (251 eyes), including 61 males (119 eyes) and 67 females (132 eyes), aged between 18 and 44 years (mean age, 22.1 years). A total of 31 patients (59 eyes) exhibited low myopia, 38 patients (76 eyes) exhibited medium myopia, 33 patients (64 eyes) exhibited high myopia and 26 patients (52 eyes) exhibited extremely high myopia. The study was conducted in accordance with the Declaration of Helsinki and approval was obtained from the Ethics Committee of Xingtai Medical College (Xingtai, China). Written informed consent was obtained from all participants.</p></sec><sec><title>Preoperative examination</title><p>All patients were subjected to a slit lamp test (SLM-2, Seetool Instrument Co., Ltd., Chongqing, China), a fundoscopic examination (YZ11D Ophthalmoscope and YZ25A Indirect Ophthalmoscope, 66 Vision-Tech Co., Ltd., Suzhou, China), an electronic optometry examination (Accuref-K 9001; Central Medical Ltd., Fukuoka, Japan), a combined optometry examination (Marco CP-690), corneal topography (ATLAS<sup>&#x000ae;</sup> 995; Carl Zeiss Meditec AG, Oberkochen, Germany), a corneal endothelium cell count, intraocular pressure measurement (AT555, Seetool Instrument Co., Ltd., Chongqing, China) and the corneal thickness was measured via ultrasound (Tomey SP-3000; Tomey Corp., Nagoya, Japan).</p></sec><sec><title>Surgical procedure</title><p>All patients were administered topical anesthesia (C<sub>17</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>&#x000b7;HCl eye drops; twice or three times into the conjunctival sac before surgery; Sam Chun Dang Pharm Co., Ltd., Tokyo, Japan) and received LASEK surgery, according to their optimal preoperative corneal refractive power, via a MEL 80&#x02122; Excimer Laser System (Carl Zeiss Meditec AG). The central 8-mm surface region of the cornea was infiltrated with 20% alcohol for 15&#x02013;25 sec under a microscope and the corneal flap was opened. Following incision using an excimer laser, the surgical area was immediately instilled with 0.02 or 0.04% MMC for a duration that was dependent on the patient&#x02019;s optimal preoperative corneal refractive power: &#x02264;&#x02212;3.00 diopters (D), 30 sec; between &#x02212;3.25 and &#x02212;6.00 D, 60 sec; between &#x02212;6.25 and &#x02212;9.00 D, 90 sec; and &#x02265;&#x02212;9.25 D, 110 sec. The surgical area was rinsed using physiological saline solution. Following resetting of the corneal flap, a soft corneal contact lens was applied.</p></sec><sec><title>Postoperative medication and follow-up</title><p>Tobramycin and dexamethasone eye drops (Guoguang Pharmaceutical Company, Hangzhou, China) were applied four times within 60 min immediately after the surgery and then a further four times in the remaining time of the same day (a total of eight times that day). Then they were administered 7 times the next day, 6 the third day, 5 the fourth day and then 4 times for the next 3 days.</p><p>One week following surgery, 0.1% fluorometholone eye drops (Osaka, Japan) were applied four times per day for three weeks, three times per day for three weeks, twice per day for three weeks and once per day for three weeks.</p><p>Diclofenac sodium eye drops (0.1%; Hubei Qianjiang Pharmaceutical Co., Ltd., Qianjiang, China) were also administered after the surgery for a week, 4 times per day. Sodium hyaluronate eye drops (Ursapharm Arzneimittel GmbH, Saarbr&#x000fc;cken, Germany) were also administered after the surgery, four times per day for whole three months.</p><p>Patients were examined once every 2&#x02013;3 weeks and were followed-up routinely for 1&#x02013;2 years postoperatively.</p></sec><sec><title>Statistical analysis</title><p>The incidence of haze visual acuity was analyzed using a &#x003c7;<sup>2</sup> test. Variations in corneal refractive power and corneal endothelial cell counts were analyzed using a t-test. P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Treatment</title><p>The incidence of haze with 0.04% MMC was 1.22%, while for 0.02% MMC, the incidence was 13.15%. The one year postoperative incidence of haze differed significantly between the groups (P&#x0003c;0.05; <xref rid="tI-etm-07-06-1591" ref-type="table">Table I</xref>). As shown in <xref rid="tII-etm-07-06-1591" ref-type="table">Table II</xref>, the one week and one year comparisons of postoperative visual acuity differed significantly between the groups (P&#x0003c;0.05). The postoperative changes in corneal refractive power at one, six and 12 months following surgery significantly differed between the groups (<xref rid="tIII-etm-07-06-1591" ref-type="table">Table III</xref>). No significant difference was identified in the density of corneal endothelial cells prior to surgery or at one, six and 12 months following surgery (P&#x0003e;0.05;<xref rid="tIV-etm-07-06-1591" ref-type="table">Table IV</xref>).</p></sec><sec><title>Complications</title><p>All patients exhibiting marginal epidermal edema were observed on day 1 and the edema was resolved by day 5. Filamentary keratitis occurred in two patients in the 0.04% MMC group (one bilateral and one unilateral) and in two patients in the 0.02% MMC group (both unilateral).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>MMC, an antineoplastic antibiotic produced by <italic>Streptomyces caespitosus</italic>, is a bi- or tri-functional alkylating agent that causes DNA cross-linking and inhibits DNA synthesis. MMC inhibits the growth of numerous types of cell and although MMC is a systemic chemotherapeutic agent, it is commonly applied locally at ophthalmic surgical sites to prevent recurrence, such as in glaucoma, pterygium excision and conjunctival resection (<xref rid="b3-etm-07-06-1591" ref-type="bibr">3</xref>,<xref rid="b4-etm-07-06-1591" ref-type="bibr">4</xref>). The activity and biotoxicity of MMC is closely associated with the dosage and usage (<xref rid="b5-etm-07-06-1591" ref-type="bibr">5</xref>,<xref rid="b6-etm-07-06-1591" ref-type="bibr">6</xref>). Previous studies identified that the biotoxicity of MMC increased with the dosage and contact time and the effect persisted following treatment (<xref rid="b7-etm-07-06-1591" ref-type="bibr">7</xref>,<xref rid="b8-etm-07-06-1591" ref-type="bibr">8</xref>). Biotoxicity of MMC is severe; however, 0.04 mg/ml MMC has been identified as safe and has been used on eye tissues during glaucoma filtration surgery. In the present study, the MMC solution was intraoperatively administered during LASEK surgery. The solution was only in contact with the surface of the cornea and did not affect surrounding cells, thereby minimizing MMC biotoxicity.</p><p>Camellin (<xref rid="b9-etm-07-06-1591" ref-type="bibr">9</xref>) and Virasch <italic>et al</italic> (<xref rid="b10-etm-07-06-1591" ref-type="bibr">10</xref>) introduced photorefractive keratectomy with an epithelial flap in 1999; this method was subsequently termed LASEK. LASEK was a revision of previous techniques and aimed to improve the postoperative time course and healing process, prevent flap trauma and offer an alternative treatment method for patients with thin corneas. Despite the similarities between LASEK and earlier technologies, the debate surrounding its legitimacy may be irrelevant if results indicate considerable superiority over previous techniques.</p><p>LASEK is an important development in refraction correction surgery; however, numerous complications remain, including haze, refractive regression and visual acuity decrease, which restrict further development of this method. Although a number of corneal epithelial cells withstand LASEK surgery and the survival of corneal epithelium cells moderately inhibits haze formation (<xref rid="b11-etm-07-06-1591" ref-type="bibr">11</xref>,<xref rid="b12-etm-07-06-1591" ref-type="bibr">12</xref>), haze remains a common complication of various techniques. Previous studies have shown that haze increases the proliferation and activity of corneal cells and results in the irregular arrangement of fibers during novel extracellular matrix synthesis (<xref rid="b13-etm-07-06-1591" ref-type="bibr">13</xref>). Although LASEK surgery retains the corneal epithelium, ethanol soaks into the matrix system valve plane located between the membrane and the dense plate, triggering postoperative healing of the corneal wound (which normally results in haze formation) (<xref rid="b14-etm-07-06-1591" ref-type="bibr">14</xref>). Excimer laser surgery is considered to be a stimulus for corneal tissue trauma, therefore, the occurrence of haze is directly associated with wound healing of the corneal tissue (<xref rid="b15-etm-07-06-1591" ref-type="bibr">15</xref>). The primary method of preventing haze formation is the use of glucocorticosteroids in the ocular region; however, glucocorticosteroid use may result in ocular hypertension, corticosteroid-induced glaucoma and cataracts. Antihyperplasia drugs have been administered in the ocular region to inhibit haze formation (<xref rid="b16-etm-07-06-1591" ref-type="bibr">16</xref>&#x02013;<xref rid="b19-etm-07-06-1591" ref-type="bibr">19</xref>), however, administering MMC in the ocular region inhibits hyperplasia of the corneal epithelium, fibroblasts and collagen fibers, as well as inhibiting haze formation. Furthermore, MMC treatment induces apoptosis of keratocytes and myofibroblasts; however, the mechanism of action underlying the inhibition of haze involves blocking the replication of keratocytes or other myofibroblast progenitor cells (<xref rid="b20-etm-07-06-1591" ref-type="bibr">20</xref>).</p><p>In the present study, two concentrations of MMC were administered during surgery to inhibit haze formation. Corneal haze formation, visual acuity, changes in refractive power, corneal endothelial cell density and corneal healing were observed. The 0.04% MMC group comprised 133 patients, (245 eyes), 58 males (112 eyes) and 75 females (113 eyes) aged between 18 and 46 years (mean age, 23.7 years). A total of 28 patients (51 eyes) exhibited low myopia, 39 patients (71 eyes) exhibited medium myopia, 31 patients (55 eyes) exhibited high myopia and 35 patients (68 eyes) exhibited extremely high myopia. The 0.02% MMC group comprised 128 patients (251 eyes), including 61 males (119 eyes) and 67 females (132 eyes) aged between 18 and 44 years (mean age, 22.1 years). A total of 31 patients (59 eyes) exhibited low myopia, 38 patients (76 eyes) exhibited medium myopia, 331 patients (64 eyes) exhibited high myopia and 26 patients (52 eyes) exhibited extremely high myopia.</p><p>In conclusion, the present study indicates that intraoperative application of 0.04% MMC solution effectively inhibits haze formation and markedly improves the outcome of LASEK surgery as compared with the administration of 0.02% MMC.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was supported by the Science Research Foundation of the Education Department, Hebei, China (grant no. 2008482).</p></ack><ref-list><title>References</title><ref id="b1-etm-07-06-1591"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JB</given-names></name><name><surname>Seong</surname><given-names>GJ</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Comparison of laser epithelial keratomileusis and photorefractive keratectomy for low to moderate myopia</article-title><source>J Cataract Refract Surg</source><volume>27</volume><fpage>565</fpage><lpage>570</lpage><year>2001</year><pub-id pub-id-type="pmid">11311625</pub-id></element-citation></ref><ref id="b2-etm-07-06-1591"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scerrati</surname><given-names>E</given-names></name></person-group><article-title>Laser in situ keratomileusis vs. laser epithelial keratomileusis (LASIK vs LASEK)</article-title><source>J Refract Surg</source><volume>17</volume><issue>Suppl 2</issue><fpage>S219</fpage><lpage>S221</lpage><year>2001</year><pub-id pub-id-type="pmid">11316025</pub-id></element-citation></ref><ref id="b3-etm-07-06-1591"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joos</surname><given-names>KM</given-names></name><name><surname>Bueche</surname><given-names>MJ</given-names></name><name><surname>Palmberg</surname><given-names>PF</given-names></name><name><surname>Feuer</surname><given-names>WJ</given-names></name><name><surname>Grajewski</surname><given-names>AL</given-names></name></person-group><article-title>One-year follow-up results of combined mitomycin C trabeculectomy and extracapsular cataract extraction</article-title><source>Opthalmology</source><volume>102</volume><fpage>76</fpage><lpage>83</lpage><year>1995</year></element-citation></ref><ref id="b4-etm-07-06-1591"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panda</surname><given-names>A</given-names></name><name><surname>Bajaj</surname><given-names>MS</given-names></name><name><surname>Balasubramanya</surname><given-names>R</given-names></name><name><surname>Prakash</surname><given-names>G</given-names></name></person-group><article-title>Topical mitomycin C for conjunctival-corneal squamous cell carcinoma</article-title><source>Am J Ophthalmol</source><volume>135</volume><fpage>122</fpage><lpage>124</lpage><year>2003</year><pub-id pub-id-type="pmid">12504721</pub-id></element-citation></ref><ref id="b5-etm-07-06-1591"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Ido</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Kitazawa</surname><given-names>Y</given-names></name></person-group><article-title>Inhibition of corneal epithelial wound healing. A comparative study of mitomycin C and 5-fluorouracil</article-title><source>Ophthalmology</source><volume>99</volume><fpage>1809</fpage><lpage>1814</lpage><year>1992</year><pub-id pub-id-type="pmid">1480395</pub-id></element-citation></ref><ref id="b6-etm-07-06-1591"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Varani</surname><given-names>J</given-names></name><name><surname>Soong</surname><given-names>HK</given-names></name><name><surname>Lichter</surname><given-names>PR</given-names></name></person-group><article-title>Effects of 5-fluorouracil and mitomycin C on cultured rabbit subconjunctival fibroblasts</article-title><source>Ophthalmology</source><volume>97</volume><fpage>1204</fpage><lpage>1210</lpage><year>1990</year><pub-id pub-id-type="pmid">2122349</pub-id></element-citation></ref><ref id="b7-etm-07-06-1591"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>HM</given-names></name><name><surname>Seitz</surname><given-names>B</given-names></name><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>LaBree</surname><given-names>L</given-names></name><name><surname>McDonnell</surname><given-names>PJ</given-names></name></person-group><article-title>In vitro effects of mitomycin-C on human keratocytes</article-title><source>J Refract Surg</source><volume>14</volume><fpage>534</fpage><lpage>540</lpage><year>1998</year><pub-id pub-id-type="pmid">9791820</pub-id></element-citation></ref><ref id="b8-etm-07-06-1591"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaw</surname><given-names>PT</given-names></name><name><surname>Sherwood</surname><given-names>MB</given-names></name><name><surname>MacKay</surname><given-names>SL</given-names></name><name><surname>Rossi</surname><given-names>MJ</given-names></name><name><surname>Schultz</surname><given-names>G</given-names></name></person-group><article-title>Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon&#x02019;s capsule fibroblasts</article-title><source>Arch Ophthalmol</source><volume>110</volume><fpage>1150</fpage><lpage>1154</lpage><year>1992</year><pub-id pub-id-type="pmid">1386726</pub-id></element-citation></ref><ref id="b9-etm-07-06-1591"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camellin</surname><given-names>M</given-names></name></person-group><article-title>LASEK may offer the advantages of both LASIK and PRK</article-title><source>Ocu Surg N Int</source><volume>10</volume><fpage>14</fpage><lpage>15</lpage><year>1999</year></element-citation></ref><ref id="b10-etm-07-06-1591"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virasch</surname><given-names>VV</given-names></name><name><surname>Majmudar</surname><given-names>PA</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name><name><surname>Vaidya</surname><given-names>NS</given-names></name><name><surname>Dennis</surname><given-names>RF</given-names></name></person-group><article-title>Reduced application time for prophylactic mitomycin C in photorefractive keratectomy</article-title><source>Ophthalmology</source><volume>117</volume><fpage>885</fpage><lpage>889</lpage><year>2010</year><pub-id pub-id-type="pmid">20163867</pub-id></element-citation></ref><ref id="b11-etm-07-06-1591"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autrata</surname><given-names>R</given-names></name><name><surname>Rehurek</surname><given-names>J</given-names></name></person-group><article-title>Laser-assisted subepithelial keratectomy for myopia: two-year follow-up</article-title><source>J Cataract Refract Surg</source><volume>29</volume><fpage>661</fpage><lpage>668</lpage><year>2003</year><pub-id pub-id-type="pmid">12686232</pub-id></element-citation></ref><ref id="b12-etm-07-06-1591"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autrata</surname><given-names>R</given-names></name><name><surname>Rehurek</surname><given-names>J</given-names></name></person-group><article-title>Laser-assisted subepithelial keratectomy and photorefractive keratectomy for the correction of hyperopia. Results of a 2-year follow-up</article-title><source>J Cataract Refract Surg</source><volume>29</volume><fpage>2105</fpage><lpage>2114</lpage><year>2003</year><pub-id pub-id-type="pmid">14670418</pub-id></element-citation></ref><ref id="b13-etm-07-06-1591"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohmann</surname><given-names>CP</given-names></name><name><surname>Gartry</surname><given-names>DS</given-names></name><name><surname>Kerr Muir</surname><given-names>M</given-names></name><name><surname>Timberlake</surname><given-names>GT</given-names></name><name><surname>Fitzke</surname><given-names>FW</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name></person-group><article-title>&#x02018;Haze&#x02019; in photorefractive keratectomy: its origins and consequences</article-title><source>Laser Light Opthalmol</source><volume>4</volume><fpage>15</fpage><lpage>34</lpage><year>1991</year></element-citation></ref><ref id="b14-etm-07-06-1591"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espana</surname><given-names>EM</given-names></name><name><surname>Grueterich</surname><given-names>M</given-names></name><name><surname>Mateo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cleavage of corneal basement membrane components by ethanol exposure in laser-assisted subepithelial keratectomy</article-title><source>J Cataract Refract Surg</source><volume>29</volume><fpage>1192</fpage><lpage>1197</lpage><year>2003</year><pub-id pub-id-type="pmid">12842689</pub-id></element-citation></ref><ref id="b15-etm-07-06-1591"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi</surname><given-names>AJ</given-names></name><name><surname>Jakobiec</surname><given-names>FA</given-names></name></person-group><article-title>Corneal wound healing: cytokines and extracellular matrix proteins</article-title><source>Int Ophthalmol Clin</source><volume>42</volume><fpage>13</fpage><lpage>22</lpage><year>2002</year><pub-id pub-id-type="pmid">12131579</pub-id></element-citation></ref><ref id="b16-etm-07-06-1591"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majmudar</surname><given-names>PA</given-names></name><name><surname>Forstot</surname><given-names>SL</given-names></name><name><surname>Dennis</surname><given-names>RF</given-names></name><etal/></person-group><article-title>Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery</article-title><source>Ophthalmolgogy</source><volume>107</volume><fpage>89</fpage><lpage>94</lpage><year>2000</year></element-citation></ref><ref id="b17-etm-07-06-1591"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigo</surname><given-names>L</given-names></name><name><surname>Scandola</surname><given-names>E</given-names></name><name><surname>Carones</surname><given-names>F</given-names></name></person-group><article-title>Scraping and mitomycin C to treat haze and regression after photorefractive keratectomy for myopia</article-title><source>J Refract Surg</source><volume>19</volume><fpage>449</fpage><lpage>454</lpage><year>2003</year><pub-id pub-id-type="pmid">12899477</pub-id></element-citation></ref><ref id="b18-etm-07-06-1591"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirza</surname><given-names>MA</given-names></name><name><surname>Qazi</surname><given-names>MA</given-names></name><name><surname>Pepose</surname><given-names>JS</given-names></name></person-group><article-title>Treatment of dense subepithelial corneal haze after laser-assisted subepithelial keratectomy</article-title><source>J Cataract Refract Surg</source><volume>30</volume><fpage>709</fpage><lpage>714</lpage><year>2004</year><pub-id pub-id-type="pmid">15050273</pub-id></element-citation></ref><ref id="b19-etm-07-06-1591"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carones</surname><given-names>F</given-names></name><name><surname>Vigo</surname><given-names>L</given-names></name><name><surname>Scandola</surname><given-names>E</given-names></name><name><surname>Vacchini</surname><given-names>L</given-names></name></person-group><article-title>Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy</article-title><source>J Cataract Refract Surg</source><volume>28</volume><fpage>2088</fpage><lpage>2095</lpage><year>2002</year><pub-id pub-id-type="pmid">12498842</pub-id></element-citation></ref><ref id="b20-etm-07-06-1591"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netto</surname><given-names>MV</given-names></name><name><surname>Mohan</surname><given-names>RR</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>PC</given-names></name><name><surname>Wilson</surname><given-names>SE</given-names></name></person-group><article-title>Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits</article-title><source>J Refract Surg</source><volume>22</volume><fpage>562</fpage><lpage>574</lpage><year>2006</year><pub-id pub-id-type="pmid">16805119</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-etm-07-06-1591" orientation="portrait" position="float"><label>Table I</label><caption><p>Incidence of haze one year following surgery (scoring according to the Fantes grading scale).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="bottom" rowspan="1">Incidence of haze, n</th><th align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="left" valign="bottom" rowspan="1">
<hr/></th><th align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total eyes, n</th><th align="center" valign="bottom" rowspan="1" colspan="1">Grade I</th><th align="center" valign="bottom" rowspan="1" colspan="1">Grade II</th><th align="center" valign="bottom" rowspan="1" colspan="1">Grade III</th><th align="center" valign="bottom" rowspan="1" colspan="1">Rate, %</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">0.04% MMC</td><td align="center" valign="top" rowspan="1" colspan="1">245</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1.22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.02% MMC</td><td align="center" valign="top" rowspan="1" colspan="1">251</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">13.15</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-07-06-1591"><p>MMC, mitomycin C.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-etm-07-06-1591" orientation="portrait" position="float"><label>Table II</label><caption><p>Comparison of postoperative visual acuity with different MMC solutions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="bottom" rowspan="1">Optimal visual acuity, n (%)</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="left" valign="bottom" rowspan="1">
<hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total eyes, n</th><th align="center" valign="bottom" rowspan="1" colspan="1">1 week</th><th align="center" valign="bottom" rowspan="1" colspan="1">3 weeks</th><th align="center" valign="bottom" rowspan="1" colspan="1">1 year</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">0.04% MMC</td><td align="center" valign="top" rowspan="1" colspan="1">245</td><td align="center" valign="top" rowspan="1" colspan="1">157 (64.08)</td><td align="center" valign="top" rowspan="1" colspan="1">245 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">243 (99.18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.02% MMC</td><td align="center" valign="top" rowspan="1" colspan="1">251</td><td align="center" valign="top" rowspan="1" colspan="1">180 (72.11)</td><td align="center" valign="top" rowspan="1" colspan="1">251 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">246 (98.01)</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-etm-07-06-1591"><p>MMC, mitomycin C.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-etm-07-06-1591" orientation="portrait" position="float"><label>Table III</label><caption><p>Changes in corneal refractive power measured in diopters (D).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="bottom" rowspan="1">Eyes exhibiting changes in corneal refractive power</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="left" valign="bottom" rowspan="1">
<hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">1 month</th><th align="center" valign="bottom" rowspan="1" colspan="1">6 months</th><th align="center" valign="bottom" rowspan="1" colspan="1">1 year</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">0.04% MMC</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.52&#x000b1;0.09</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.29&#x000b1;0.15</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.35&#x000b1;0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.02% MMC</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.67&#x000b1;0.11</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.58&#x000b1;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.54&#x000b1;0.18</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-etm-07-06-1591"><p>Values are expressed as mean &#x000b1; SD. MMC, mitomycin C.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-etm-07-06-1591" orientation="portrait" position="float"><label>Table IV</label><caption><p>Density of corneal endothelial cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="4" align="center" valign="bottom" rowspan="1">Density of corneal endothelial cells, cells/mm<sup>2</sup></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="4" align="left" valign="bottom" rowspan="1">
<hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Preoperative</th><th align="center" valign="bottom" rowspan="1" colspan="1">Postoperative 1 month</th><th align="center" valign="bottom" rowspan="1" colspan="1">Postoperative 6 months</th><th align="center" valign="bottom" rowspan="1" colspan="1">Postoperative 12 months</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">0.04% MMC</td><td align="center" valign="top" rowspan="1" colspan="1">2,994.01&#x000b1;321.89</td><td align="center" valign="top" rowspan="1" colspan="1">2,974.89&#x000b1;339.87</td><td align="center" valign="top" rowspan="1" colspan="1">3,001.02&#x000b1;306.92</td><td align="center" valign="top" rowspan="1" colspan="1">3,011.18&#x000b1;321.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.02% MMC</td><td align="center" valign="top" rowspan="1" colspan="1">3,005.92&#x000b1;382.54</td><td align="center" valign="top" rowspan="1" colspan="1">2,996.69&#x000b1;374.19</td><td align="center" valign="top" rowspan="1" colspan="1">2,988.37&#x000b1;367.33</td><td align="center" valign="top" rowspan="1" colspan="1">3,000.05&#x000b1;299.84</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-etm-07-06-1591"><p>Values are expressed as mean &#x000b1; SD. MMC, mitomycin C.</p></fn></table-wrap-foot></table-wrap></floats-group></article>